miteman
Exelixis (NASDAQ:EXEL) announced late Friday that it filed a lawsuit against Cipla, alleging that the Indian drugmaker has violated its patents related to the company’s lead asset, Cabometyx.
The lawsuit filed in a Delaware district court on Thursday follows Cipla’s move to amend its previously filed marketing application, targeted at FDA authorization for additional doses of its Cabometyx version.
With its lawsuit, the Alameda, California-based cancer drugmaker seeks a court order to prevent Cipla from receiving FDA authorization for its Cabometyx versions before the expiry of relevant patents.
Exelixis (EXEL) first filed a lawsuit against Mumbai-based Cipla in March 2023 after the generic drugmaker submitted its original Abbreviated New Drug Application for its Cabometyx generic early last year.
Cabometyx, a tyrosine kinase inhibitor indicated in the U.S. for liver and kidney cancer, added $1.6B in net product revenue for Exelixis (EXEL) in 2023, with ~17% YoY growth.
Source link
